University of Houston researchers and their students are developing a new software technology, based on artificial intelligence, for advancing cell-based immunotherapy to treat cancer and other diseases.
University of Houston researchers and their students are developing a new software technology, based on artificial intelligence, for advancing cell-based immunotherapy to treat cancer and other diseases.
CellChorus Inc., a spinoff from the University of Houston, is commercializing the UH-developed Time-lapse Imaging Microscopy In Nanowell Grids™ platform for dynamic single-cell analysis with label-free analysis. Now they’ve received a $2.5 million grant from the National Center for Advancing Translational Sciences of the National Institutes of Health to fast-track the development of an advanced “label-free” version of this technology in partnership with the University of Houston.
Badri Roysam, Hugh Roy and Lillie Cranz Cullen University Professor of Electrical and Computer Engineering at the University of Houston, is collaborating with Professor Navin Varadarajan on the project. Varadarjan is an M.D. Anderson Professor, Chemical and Biomolecular Engineering also at UH and co-founder of CellChorus.
“This is an opportunity to leverage artificial intelligence methods for advancing the life sciences,” said Roysam. “We are especially excited about its applications to advancing cell-based immunotherapy to treat cancer and other diseases.”
Read more at University of Houston
Image: Badri Roysam, Hugh Roy and Lillie Cranz Cullen University Professor of Electrical and Computer Engineering at the University of Houston, is developing new software technology, based on artificial intelligence, for advancing cell-based immunotherapy to treat cancer and other diseases. (Credit: University of Houston)
